ASN 100

Drug Profile

ASN 100

Alternative Names: ASN-1 and ASN-2; ASN-100

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arsanis Biosciences
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Staphylococcal infections

Most Recent Events

  • 09 Oct 2017 Additional adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers released by Arsanis
  • 09 Oct 2017 Additional preclinical pharmacodynamics data in Staphylococcal infections released by Arsanis
  • 04 Oct 2017 Adverse events data from a phase I trial in Staphylococcus infections presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top